A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
PMID: 39928262
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 Feb 03; 8(2):e2460243.
PMID: 39960669
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
PMID: 39561272
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2024 Dec 09; 10781552241305417.
PMID: 39648753
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
PMID: 39579248
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers.
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers. Clin Cancer Res. 2024 Nov 19.
PMID: 39561272
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
PMID: 39510069
Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer.
Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer. Sci Adv. 2024 Oct 25; 10(43):eadp2622.
PMID: 39441940
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer. J Oncol Pharm Pract. 2024 Oct 13; 10781552241289581.
PMID: 39397422
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy. Breast Cancer Res Treat. 2025 Jan; 209(1):147-159.
PMID: 39305392